SQI Diagnostics, a Toronto-based developer of microarray-based tests, last week announced that it had closed a CDN$1.6 million ($1.3 million) second tranche of a non-brokered private placement of stock, bringing to CDN$4.6 million the total proceeds from the placement.

The publicly traded company, which closed the CDN$3 million first tranche last month, said that as a result of the round, Toronto-based FW Thompson & Company now controls 18 percent of the company’s outstanding shares. It did not disclose the names of all investors involved in the placement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.